<rdf:RDF xmlns:rdf="http://www.openarchives.org/OAI/2.0/rdf/" xmlns:ow="http://www.ontoweb.org/ontology/1#" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:ds="http://dspace.org/ds/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/rdf/ http://www.openarchives.org/OAI/2.0/rdf.xsd">
   <ow:Publication rdf:about="oai:digibug.ugr.es:10481/72556">
      <dc:title>New Formulations Loading Caspofungin for Topical Therapy of Vulvovaginal Candidiasis</dc:title>
      <dc:creator>Pérez González, Noelia</dc:creator>
      <dc:creator>Nardi Ricart, Anna</dc:creator>
      <dc:creator>Soriano Ruiz, José Luis</dc:creator>
      <dc:creator>Clares Naveros, Beatriz</dc:creator>
      <dc:subject>Vulvovaginal candidiasis</dc:subject>
      <dc:subject>Antifungal therapy</dc:subject>
      <dc:subject>Caspofungin</dc:subject>
      <dc:subject>Vaginal mucosal delivery</dc:subject>
      <dc:subject>Mucoadhesive hydrogel</dc:subject>
      <dc:subject>Thermoreversible hydrogel</dc:subject>
      <dc:description>This research was funded by the Spanish National Research Council (CSIC), project no.&#xd;
202080E231, and the Agreement with the University of Barcelona and the University of Granada&#xd;
(Official State Gazette 311, on 27 November 2020).</dc:description>
      <dc:description>Vulvovaginal candidiasis (VVC) poses a significant problem worldwide affecting women&#xd;
from all strata of society. It is manifested as changes in vaginal discharge, irritation, itching and&#xd;
stinging sensation. Although most patients respond to topical treatment, there is still a need for&#xd;
increase the therapeutic arsenal due to resistances to anti-infective agents. The present study was&#xd;
designed to develop and characterize three hydrogels of chitosan (CTS), Poloxamer 407 (P407)&#xd;
and a combination of both containing 2% caspofungin (CSP) for the vaginal treatment of VVC.&#xd;
CTS was used by its mucoadhesive properties and P407 was used to exploit potential advantages&#xd;
related to increasing drug concentration in order to provide a local effect. The formulations were&#xd;
physically, mechanically and morphologically characterized. Drug release profile and ex vivo vaginal&#xd;
permeation studies were performed. Antifungal efficacy against different strains of Candida spp. was&#xd;
also evaluated. In addition, tolerance of formulations was studied by histological analysis. Results&#xd;
confirmed that CSP hydrogels could be proposed as promising candidates for the treatment of VVC.</dc:description>
      <dc:date>2022-01-31T11:21:11Z</dc:date>
      <dc:date>2022-01-31T11:21:11Z</dc:date>
      <dc:date>2021-12-12</dc:date>
      <dc:type>info:eu-repo/semantics/article</dc:type>
      <dc:identifier>Pérez-González, N... [et al.]. New Formulations Loading Caspofungin for Topical Therapy of Vulvovaginal Candidiasis. Gels 2021, 7, 259. [https://doi.org/10.3390/gels7040259]</dc:identifier>
      <dc:identifier>http://hdl.handle.net/10481/72556</dc:identifier>
      <dc:identifier>10.3390/gels7040259</dc:identifier>
      <dc:language>eng</dc:language>
      <dc:rights>http://creativecommons.org/licenses/by/3.0/es/</dc:rights>
      <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
      <dc:rights>Atribución 3.0 España</dc:rights>
      <dc:publisher>MDPI</dc:publisher>
   </ow:Publication>
</rdf:RDF>